Clinical Trials Logo

Clinical Trial Summary

The aim of this study is to investigate tasimelteon vs. placebo on sleep disturbances of individuals with Smith-Magenis Syndrome.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT02231008
Study type Interventional
Source Vanda Pharmaceuticals
Contact
Status Completed
Phase Phase 2/Phase 3
Start date September 2015
Completion date January 2022

See also
  Status Clinical Trial Phase
Completed NCT00004351 - Study of Phenotype and Genotype Correlations in Patients With Contiguous Gene Deletion Syndromes N/A
Completed NCT02776215 - Study of the Pharmacokinetics and Safety of Tasimelteon in Children and Adolescents Phase 1
Recruiting NCT05116904 - Smith Magenis Syndrome and Autism Spectrum Disorders N/A
Recruiting NCT04768803 - Ghrelin in Patients With a Rare Disease Associated With Intellectual Disability, and Hyperphagia, and/or Overweight, and/or Obesity